USP Announces New Standards for Heparin and Glycerin

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Pharmacopeial (USP) Convention has announced new standards for heparin and glycerin.

Rockville, MD (Feb. 4)-The US Pharmacopeial (USP) Convention has announced new standards for heparin and glycerin. USP revised the heparin standard at the request of the US Food and Drug Administration, in response to adulterated heparin product with over-sulfated chondroitin, which resulted in the deaths of 200 people. Glycerin, a sweetener and binding agent, has been adulterated in the past by dilution with diethylene glycol. The new standards for glycerin becomes official in May 2009, and the new standards for heparin becomes official in August 2009 after a public comment period. All manufacturers of these products are required to comply with the standards.

The US Food and Drug Administration requested a new glycerin standard that establishes limits for diethylene glycol and revises other “high risk” articles that have similar applications. FDA also requested a revised heparin monograph to detect the presence of over-sulfated chondroitin sulfate. In addition, the modernized heparin monograph aims to provide improved analytical methods, improved measurement of heparin activity, and the development of associated reference standards (i.e., heparin identity, heparin potency, oversulfated chondroitin sulfate, and dermatan sulfate).

“These new USP quality standards provide better assurance of the quality of marketed products by using appropriate and modern analytical methods,” says Moheb Nasr, PhD, director of the Office of New Drug Quality Assessment (ONDQA), at FDA's Center for Drug Evaluation and Research (CDER), in a USP press release. “This provides a considerable safeguard for citizens of the United States and the world by helping to prevent fraudulent suppliers from adding components that in the past have eluded existing identity tests due to similar properties. The new standards represent a significant improvement to the safety nets that keep substandard drugs from reaching the marketplace. FDA is pleased to have worked together with USP on this effort.”

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes